Can amiodarone prevent sudden cardiac death in patients with hemodynamically tolerated sustained ventricular tachycardia and coronary artery disease?
One of the most important challenges in today's cardiology is prevention of sudden cardiac death in high risk patients with coronary artery disease (CAD). Sustained hemodynamically tolerated ventricular tachycardia (HTVT) comprises up to 30% of all cases of monomorphic ventricular tachycardia in patients with CAD. While there is a consensus on treatment of hemodynamically unstable sustained ventricular tachycardia in patients with CAD, some controversies regarding the proper treatment of HTVT exist. We re-examined existing clinical evidence, controversies and current guidelines on the treatment of HTVT in patients with CAD and demonstrated that compared to implantable cardioverter-defibrillator, amiodarone is not an acceptable therapeutic option in patients with ischemic heart disease who suffer from HTVT.
Arya
Arash
A
Department of Pacemaker and Electrophysiology, Rajaie Cardiovascular Medical Center, Mellat Park, Vali-Asr Avenue, Tehran 1996911151, Iran. arya@rhc.ac.ir
Haghjoo
Majid
M
Sadr-Ameli
Mohammad Ali
MA
D000638:Amiodarone / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D017147:Defibrillators, Implantable; D006801:Humans; D017180:Tachycardia, Ventricular / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology
D000638:Amiodarone